@entity2747 ( @entity2747 ) is estimated to affect a significant proportion of the population worldwide. Of those affected, the majority reside in developing countries. In the developing world, more than 80% of the @entity1 afflicted with @entity726 are unaware that they have the disease, and @entity227 from @entity2747 is more severe than from primary @entity1538 . Considering the paucity of resources and competing opportunity costs, it is imperative that the developing world extrapolates current literature and exiting data sensibly, and develops cost-effective strategies for the detection and management of angle closure @entity726 . The number needed to treat (NNT) was used to extrapolate the trials for an individual @entity1 . To extrapolate to the overall population (where applicable) the authors used the population attributable risk percentage (PAR%). For individual @entity1 care, treatment of a primary angle closure suspect (PACS) has an NNT of 6 over 5 years to prevent one @entity1 progressing to primary angle closure (PAC). The NNT for PAC to prevent @entity2747 over 5 years is 5. The 'effective' PAR% for PACS is 56.4% and the 'effective' PAR% for PAC is 65%. This suggests both PACS and PAC are important health burdens but because of the absence of a good screening test and the opportunity costs involved, population-based screening will probably be unfeasible in developing countries.

XXXX : a developing world perspective.

@entity1 :: ('9606', 'Species') :: ['patient', 'people'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment'] @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity2747 :: ('MESH:D015812', 'Disease') :: ['PACG', 'Primary angle closure glaucoma']
@entity2747 :: (MESH:D015812,Disease) :: ['Primary angle closure glaucoma']
